Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | EP300 | Q09472 | 6/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745685 | 0.88 | PTPN11 (0.42) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL13746471 | 0.86 | PTPN11 (0.43) | PTPN11BRD4HTR6 | |
| SCHEMBL13745691 | 0.83 | BRD4 (0.41) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL13746484 | 0.83 | PTPN11 (0.41) | PTPN11BRD4 | |
| SCHEMBL13745607 | 0.83 | GAK (0.43) | PTPN11BRD4PDPK1HTR6 | |
| SCHEMBL1487531 | 0.82 | HTR6 (0.38) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL8488870 | 0.82 | BRD4 (0.41) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL8488593 | 0.82 | HTR6 (0.38) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL13746469 | 0.82 | PTPN11 (0.39) | PTPN11BRD4PDPK1HTR6CA12 | |
| SCHEMBL13746238 | 0.81 | PTPN11 (0.49) | PTPN11BRD4PDPK1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PTPN11 1694/4885BRD4 1339/4885PDPK1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.